EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Impact of atrial fibrillation diagnosis-to-ablation time on 24-month efficacy and safety outcomes in the Cryo Global Registry

Dennis Lawin iD, Christoph Stellbrink iD, Kyoung-Ryul Julian Chun iD, Cheng-Hung Li, Kelly A van Bragt iD, Fred Kueffer iD, Jada M Selma iD, Il-Young Oh iD, Jean Manuel Herzet, Junichi Nitta iD, Ting Yung Chang iD, Thorsten Lawrenz iD

Europace · 2025

DOI: 10.1093/europace/euaf008 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Europace, 2025. Verfasst von Dennis Lawin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Intensive Care Medicine, Bielefeld University, Medical School and University Medical Center OWL, Public Hospital of Biel…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Cryosurgery, Time-to-Treatment. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medtronic, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Early rhythm control therapy in atrial fibrillation (AF) results in higher freedom from atrial arrhythmia (AA) recurrence and improved cardiovascular outcomes. The optimal timing of cryoballoon ablation (CBA) is unknown. Methods and results We evaluated AA recurrence and procedure-related complications of early vs. late CBA (≤12 vs. >12 months from diagnosis) in patients enrolled in the prospective Cryo Global Registry (121 centres in 37 countries, NCT02752737). A total of 3447 subjects were followed through 12 months and 1220 through 24 months. In summary, 1573 patients (46%) had early ablation at a median (IQR) of 0.3 (0.1–0.6) years from AF diagnosis (age 62 ± 12 years., 35.8% female, 71.4% paroxysmal), and 1874 (54%) had late ablation at a median of 3.4 (1.9–6.7) years after diagnosis (age 61 ± 11 years, 36.2% female, 75.0% paroxysmal). Early ablation patients were less hypertensive (53.5% vs. 57.9%, P = 0.01) and less symptomatic (1.5 ± 1.1 vs. 1.8 ± 1.1 symptoms/patient, P < 0.01) and had smaller left atrial diameters (41 ± 7 mm vs. 42 ± 7 mm, P < 0.01). Freedom from AA recurrence was 81.5% (95% CI: 78.7–83.9%) in the early vs. 71.7% (95% CI: 68.9–74.3%) in the late ablation group at 24 months (P < 0.01). The risk of cardioversion was 41% lower in the early ablation group [HRAdj: 0.59 (0.42–0.83), P < 0.01]. Serious procedure-related adverse events occurred in 2.4 and 3.5% of patients in the early and late ablation groups (P = 0.045), respectively.

Conclusion

CBA within 12 months from AF diagnosis resulted in higher freedom from AA recurrence and is associated with fewer safety events in a real-world evaluation. Clinical trial registration https://clinicaltrials.gov/ct2/show/NCT02752737

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCryosurgeryTime-to-TreatmentAgedFemaleHumansMaleMiddle AgedProspective StudiesRecurrenceRegistriesRisk FactorsTime FactorsTreatment Outcome

Stichwörter der Autor:innen

Atrial fibrillationCatheter ablationCryoballoonEarly ablationRegistry

Autor:innen und Institutionen

  • Department of Cardiology and Intensive Care Medicine, Bielefeld University, Medical School and University Medical Center OWL, Public Hospital of Bielefeld, Teutoburger Str. 50, D-33604 Bielefeld, Germany.
  • Cardioangiologisches Centrum Bethanien, Frankfurt, Germany.
  • Taichung Veterans General Hospital, Taichung, Taiwan.
  • Medtronic, Inc., Minneapolis, MN, USA.
  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul, Republic of Korea.
  • Centre Hospitalier Régional de la Citadelle, Liège, Belgium.

ORCID-Profile: Dennis Lawin, Christoph Stellbrink, Kyoung-Ryul Julian Chun, Kelly A van Bragt, Fred Kueffer, Jada M Selma, Il-Young Oh, Junichi Nitta, Ting Yung Chang, Thorsten Lawrenz

Förderung

  • Medtronic, Inc

Zitieren

APA

Lawin, D., Stellbrink, C., Chun, K. J., Li, C. H., van Bragt, K. A., Kueffer, F., Selma, J. M., Oh, I. Y., Herzet, J. M., Nitta, J., Chang, T. Y., & Lawrenz, T. (2025). Impact of atrial fibrillation diagnosis-to-ablation time on 24-month efficacy and safety outcomes in the Cryo Global Registry. Europace. https://doi.org/10.1093/europace/euaf008

Vancouver

Lawin D, Stellbrink C, Chun KJ, Li CH, van Bragt KA, Kueffer F, et al. Impact of atrial fibrillation diagnosis-to-ablation time on 24-month efficacy and safety outcomes in the Cryo Global Registry. Europace. 2025. doi:10.1093/europace/euaf008

BibTeX
@article{Lawin2025,
  author = {Lawin, Dennis and Stellbrink, Christoph and Chun, Kyoung-Ryul Julian and Li, Cheng-Hung and van Bragt, Kelly A and Kueffer, Fred and Selma, Jada M and Oh, Il-Young and Herzet, Jean Manuel and Nitta, Junichi and Chang, Ting Yung and Lawrenz, Thorsten},
  title = {Impact of atrial fibrillation diagnosis-to-ablation time on 24-month efficacy and safety outcomes in the Cryo Global Registry},
  journal = {Europace},
  year = {2025},
  doi = {10.1093/europace/euaf008}
}
Kostenlos starten →